About the Company
Compugen Ltd. (Hebrew: קומפיוג'ן) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on COMPUGEN LTD
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look ...
Compugen (NASDAQ:CGEN) has had a rough three months with its share price down 19%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could ...
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
NasdaqCM:CGEN 1 Year Share Price vs Fair Value Explore Compugen's Fair Values from the Community and select yours ...
Compugen Ltd. (CGEN) latest stock news and headlines – Yahoo Finance
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Dr. Roy Granit, Head of Computational ...
Compugen to Release Second Quarter 2025 Results on ... - Morningstar
HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target ...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate ...
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to ...
Compugen Analyst Ratings and Price Targets | NASDAQ:CGEN | Benzinga
Compugen Ltd has a consensus price target of $5.42 based on the ratings of 6 analysts. The high is $13 issued by EF Hutton on August 7, 2023. The low is $0.5 issued by Jefferies on February 8, 2023.
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 ...
HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from ...
Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune ...
Contacts Compugen Ltd. Tsipi Haitovsky Global Media Liaison +972-52-598-9892 tsipih@cgen.com ...
CGEN | Compugen Ltd. Profile | MarketWatch
Company Profile Compugen Ltd. Azrieli Center 26 Harokmim Street Building D Holon, TA 58858 Phone972 3 765-8585 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and Compugen Ltd. CGEN may be one such company. The firm has earnings coming up pretty soon, and events are ...
Bristol-Myers' Collaboration Deal: Accelerating Potential Creation ...
Summary On October 11, Compugen announced a collaboration deal with Bristol-Myers Squibb; includes $12M investment in Compugen, and the supply of Opdivo at no cost for Compugen's Phase 1 COM-701 ...
Similar Companies
Loading the latest forecasts...